Mesothelin Expression: Clinical Trials

2 completed, 1 terminated. 2 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	2	Completed 2
Phase 2	2	Completed 1, Terminated 1

Follow Mesothelin Expression: new trials by email Literature Review of Mesothelin Expression trials Research Report on Mesothelin Expression

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) LMB-100, pembrolizumab, Mesothelin Expression - Lung Cancer, Non-Small Cell Lung Cancer	Phase 2	Terminated	National Cancer Institute (NCI)	6	2019-09-11	2024-04-16
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors LMB-100, Tofacitinib, Mesothelin Expression - Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma	Phase 1	Completed	National Cancer Institute (NCI)	19	2019-08-29	2023-08-01
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors LMB-100, Nab-Paclitaxel, Mesothelin Expression - Neoplasms, Pancreatic Neoplasms	Phase 1 / Phase 2	Completed	National Cancer Institute (NCI)	40	2016-08-03	2022-03-15

Conditions studied

Adenocarcinoma (1)  ·  Adenocarcinoma of Lung (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Cholangiocarcinoma (1)  ·  Lung Neoplasms (1)  ·  Neoplasms (1)  ·  Pancreatic Neoplasms (1)

Sponsors

National Cancer Institute (NCI) (3)

Countries

United States (3)

Top investigators

Christine C Alewine, M.D. (2)  ·  Azam Ghafoor, M.D. (1)

Results publications

PMID 36208017, PMID 38706610